Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kronos Bio Inc
(NQ:
KRON
)
0.9953
-0.0029 (-0.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
22,799
Open
0.9800
Bid (Size)
0.9600 (10)
Ask (Size)
1.110 (10)
Prev. Close
0.9982
Today's Range
0.9800 - 1.010
52wk Range
0.6900 - 1.600
Shares Outstanding
56,769,091
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
KRON stock results show that Kronos Bio beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
August 08, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Performance
YTD
-17.06%
-17.06%
1 Month
-19.08%
-19.08%
3 Month
+25.19%
+25.19%
6 Month
-19.08%
-19.08%
1 Year
-28.40%
-28.40%
More News
Read More
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
July 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
June 13, 2024
Via
Benzinga
Recap: Kronos Bio Q4 Earnings
March 21, 2024
Via
Benzinga
Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
June 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
June 11, 2024
Via
Benzinga
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 24, 2024
Via
Benzinga
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
May 22, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
May 21, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
KRON Stock Earnings: Kronos Bio Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Kronos Bio Reports First-Quarter 2024 Financial Results
May 09, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q4 2023
March 21, 2024
Via
InvestorPlace
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
March 21, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
March 07, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
March 05, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
February 27, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
January 25, 2024
From
Kronos Bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 18, 2024
Via
Benzinga
Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study
December 19, 2023
Via
Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
December 19, 2023
Via
Benzinga
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
December 18, 2023
From
Kronos Bio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.